-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120

Benzinga·11/04/2026 14:25:02
语音播报
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.